DEFECTIVE RING-A REDUCTION OF CORTISOL AS THE MAJOR METABOLIC ERROR IN THE SYNDROME OF APPARENT MINERALOCORTICOID EXCESS

被引:88
作者
ULICK, S
TEDDE, R
WANG, JZ
机构
[1] CORNELL UNIV, MED CTR, NEW YORK HOSP, COLL MED, CTR CARDIOVASC, NEW YORK, NY 10021 USA
[2] CLIN MED UNIV SASSARI, SASSARI, ITALY
[3] VET AFFAIRS HOSP, BRONX, NY 10468 USA
[4] CUNY MT SINAI SCH MED, DEPT MED, NEW YORK, NY 10029 USA
关键词
D O I
10.1210/jc.74.3.593
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Impaired peripheral metabolism of cortisol in the syndrome of apparent mineralocorticoid excess is currently understood to be causally related to the severe but otherwise unexplained manifestations of mineralocorticoid excess. A normally ambivalent mineralocorticoid receptor responding equally well to glucocorticoids and mineralocorticoids requires prereceptor inactivation of glucocorticoids to elicit a specific mineralocorticoid effect. The failed inactivation step in the form of the syndrome of apparent mineralocorticoid excess first described (type 1) involves the 11-beta-hydroxydehydrogenation of cortisol to cortisone. In another form of the syndrome (type 2) this conversion occurs normally in the face of otherwise similar clinical and biochemical features. Markedly decreased cortisol metabolic clearance in the type 2 form suggested impairment of a major component of that clearance, ring A reduction. A noninvasive method was developed for measuring the conversion of cortisol to tetrahydrocortisol and allotetrahydrocortisol, and this step was found to be profoundly decreased in both type 1 and type 2 forms. Thus, the major abnormality in the peripheral metabolism of cortisol common to both forms involved ring A reduction, not 11-beta-hydroxydehydrogenation. Since ring A reduction was better correlated with the manifestation of mineralocorticoid excess in both forms of the syndrome, this step might also be a normal major prereceptor mechanism conferring mineralocorticoid specificity.
引用
收藏
页码:593 / 599
页数:7
相关论文
共 43 条
[1]   THE PATHOGENESIS OF PSEUDOHYPERALDOSTERONISM FROM CARBENOXOLONE [J].
ARMANINI, D ;
SCALI, M ;
ZENNARO, MC ;
KARBOWIAK, I ;
WALLACE, C ;
LEWICKA, S ;
VECSEI, P ;
MANTERO, F .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1989, 12 (05) :337-341
[2]  
ARMANINI D, 1985, AM J PHYSIOL, P88
[3]   CLONING OF HUMAN MINERALOCORTICOID RECEPTOR COMPLEMENTARY-DNA - STRUCTURAL AND FUNCTIONAL KINSHIP WITH THE GLUCOCORTICOID RECEPTOR [J].
ARRIZA, JL ;
WEINBERGER, C ;
CERELLI, G ;
GLASER, TM ;
HANDELIN, BL ;
HOUSMAN, DE ;
EVANS, RM .
SCIENCE, 1987, 237 (4812) :268-275
[4]   THE NEURONAL MINERALOCORTICOID RECEPTOR AS A MEDIATOR OF GLUCOCORTICOID RESPONSE [J].
ARRIZA, JL ;
SIMERLY, RB ;
SWANSON, LW ;
EVANS, RM .
NEURON, 1988, 1 (09) :887-900
[5]   SPIRONOLACTONE-REVERSIBLE RICKETS ASSOCIATED WITH 11-BETA-HYDROXYSTEROID DEHYDROGENASE-DEFICIENCY SYNDROME [J].
BATISTA, MC ;
MENDONCA, BB ;
KATER, CE ;
ARNHOLD, IJP ;
ROCHA, A ;
NICOLAU, W ;
BLOISE, W .
JOURNAL OF PEDIATRICS, 1986, 109 (06) :989-993
[6]   CHARACTERIZATION OF RAT-BRAIN ALDOSTERONE RECEPTORS REVEALS HIGH-AFFINITY FOR CORTICOSTERONE [J].
BEAUMONT, K ;
FANESTIL, DD .
ENDOCRINOLOGY, 1983, 113 (06) :2043-2051
[7]   DISTRIBUTION OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE ALONG THE RABBIT NEPHRON [J].
BONVALET, JP ;
DOIGNON, I ;
BLOTCHABAUD, M ;
PRADELLES, P ;
FARMAN, N .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (03) :832-837
[8]  
DEKLOET ER, 1984, J STEROID BIOCHEM, V20, P367, DOI 10.1016/0022-4731(84)90235-8
[9]   DIFFERENCES IN CORTICOSTERONE AND DEXAMETHASONE BINDING TO RAT-BRAIN AND PITUITARY [J].
DEKLOET, R ;
WALLACH, G ;
MCEWEN, BS .
ENDOCRINOLOGY, 1975, 96 (03) :598-609
[10]  
EDWARDS C R W, 1985, Journal of Endocrinology, V104, P53